Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020

During the last two decades, kinase inhibitors have become the major drug class for targeted cancer therapy. Although the number of approved kinase inhibitors increases rapidly, comprehensive in vitro profiling and comparison of inhibitor activities is often lacking in the public domain. Here we rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Kooijman, Jeffrey J., van Riel, Wilhelmina E., Dylus, Jelle, Prinsen, Martine B. W., Grobben, Yvonne, de Bitter, Tessa J. J., van Doornmalen, Antoon M., Melis, Janneke J. T. M., Uitdehaag, Joost C. M., Narumi, Yugo, Kawase, Yusuke, de Roos, Jeroen A. D. M., Willemsen-Seegers, Nicole, Zaman, Guido J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516332/
https://www.ncbi.nlm.nih.gov/pubmed/36185300
http://dx.doi.org/10.3389/fonc.2022.953013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516332/
https://www.ncbi.nlm.nih.gov/pubmed/36185300
http://dx.doi.org/10.3389/fonc.2022.953013

Ejemplares similares